Agilent Technologies, Inc. (A) · Nov 20, 2026 · Exec change
Director retirement — Board reduced from 11 to 10 effective December 1, 2026
Agilent’s board change is a planned director retirement, with no operating disagreement and no replacement announced as the board shrinks to 10.
Agilent is in an execution phase as a laboratory-technology company serving life sciences, diagnostics and applied markets through three operating segments, with recent growth led by its life-sciences and advanced-technology businesses. This filing does not alter that operating story: George Scangos will retire from the board on December 1, and the company will reduce the board from 11 members to 10. 〔0〕
This is governance housekeeping, not a strategic change. The filing says the retirement was not caused by any disagreement with Agilent or the board, and it names no replacement, suggesting the board is comfortable operating with fewer directors rather than signaling a change in business direction. 〔1〕
Bottom line: A modest board-composition change with no disclosed operational or strategic consequence. It leaves Agilent’s business trajectory essentially unchanged.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!